# Beijing Shangshi Xiaozhong Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-shangshi-xiaozhong-technology-co

- Industry: Consumer Services
- Headquarters: Beijing, China
- Website: www.yi23.net
- Total disclosed funding: $80M
- Latest round: Series C (Sep 6, 2017)
- Investors on record: 11

## About

Beijing Shangshi Xiaozhong Technology Co., Ltd. is a health and wellness company specializing in natural products, including supplements and herbal extracts aimed at enhancing vitality and overall well-being for health-conscious consumers.Founded in 2015 and headquartered in Beijing, China, Beijing Shangshi Xiaozhong Technology Co., Ltd. focuses on providing health and wellness solutions through natural products. The company has participated in a total of 7 deals, with its most recent funding round being a Series C that raised USD 50.00 mn from notable investors including Alibaba Innovation Ventures and Sequoia Capital on July 9, 2021. The company is led by CEO Mengyuan Liu.The company specializes in a diverse range of health and wellness products, prominently featuring extracts, powders, and supplements sourced from wild plants and natural ingredients. Their primary offerings include enzymatic probiotics, herbal extracts, and superfood powders, which are designed to support various health needs such as digestive health, energy enhancement, and immune support. Targeted end-use cases address specific health concerns, including heart health, weight loss, and wellness during menopause. These products are marketed to health-conscious consumers, including individuals seeking natural alternatives to conventional health solutions. The company serves a growing customer base primarily located in North America and Europe, aiming to reach audiences that prioritize holistic health and regenerative practices.The company's revenue model is based on direct-to-consumer sales through their online platform, where products are sold either individually or as part of curated wellness packages. Transactions are structured primarily as B2C sales, with customers purchasing items such as their flagship "Fulvic Ionic Minerals" and various herbal extracts. Pricing plans are designed to cater to different consumer needs, allowing for bulk purchases and subscription models. The product range is positioned in a price tier that reflects the premium nature of the ingredients, ensuring that customers perceive value in their investment towards health and wellness. Overall, the company's revenue generation strategy is focused on leveraging the growing trend of natural health solutions among discerning consumers.In July 2021, Beijing Shangshi Xiaozhong Technology Co., Ltd. discontinued its operations.

## Funding rounds

- Series C, Sep 6, 2017, $50M — Hong Shan, UOB Venture Management, GSR Ventures, SB China Venture Capital, IDG Capital, Panlin Capital, ZhenFund, Zhizhuo Capital, Alibaba Innovation Ventures
- Series B, Mar 17, 2017, $20M — UOB Venture Management, GSR Ventures, IDG Capital, Panlin Capital, ZhenFund, Zhizhuo Capital, Hangzhou Feitongfanxiang Investment Management
- Series A, Apr 25, 2016, $10M — GSR Ventures, IDG Capital, ZhenFund, Crystal Stream
- Series A, Oct 6, 2015 — GSR Ventures

## Investors

- GSR Ventures (https://capitalatlas.ai/funds/gsr-ventures) — Series A, Series B, Series C
- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series A, Series B, Series C
- ZhenFund (https://capitalatlas.ai/funds/zhenfund) — Series A, Series B, Series C
- Crystal Stream (https://capitalatlas.ai/funds/crystal-stream) — Series A
- UOB Venture Management (https://capitalatlas.ai/funds/uob-venture-management) — Series B, Series C
- Panlin Capital (https://capitalatlas.ai/funds/panlin-capital) — Series B, Series C
- Zhizhuo Capital (https://capitalatlas.ai/funds/zhizhuo-capital) — Series B, Series C
- Hangzhou Feitongfanxiang Investment Management — Series B
- Hong Shan — Series C
- SB China Venture Capital (https://capitalatlas.ai/funds/sb-china-venture-capital) — Series C
- Alibaba Innovation Ventures — Series C